maleimide has been researched along with daunorubicin in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jóźwiak, Z; Szwarocka, A | 1 |
| Carstensen, EV; Jensen, LH; Jensen, PB; Langer, SW; Renodon-Corniere, A; Sehested, M; Søkilde, B; Wessel, I | 1 |
| Cheng, M; Chu, T; Larregieu, CA; Li, H; Li, W; Liu, M; Mao, SJ; Yan, B | 1 |
3 other study(ies) available for maleimide and daunorubicin
| Article | Year |
|---|---|
The effect of daunorubicin and glutaraldehyde treatment on the structure of erythrocyte membrane.
Topics: Daunorubicin; Drug Synergism; Electron Spin Resonance Spectroscopy; Erythrocyte Membrane; Erythrocytes; Glutaral; Humans; Maleimides; Membrane Fluidity; Spectrometry, Fluorescence; Spin Labels; Viscosity | 1999 |
Maleimide is a potent inhibitor of topoisomerase II in vitro and in vivo: a new mode of catalytic inhibition.
Topics: Antineoplastic Agents, Phytogenic; Catalysis; Cell Survival; Cells, Cultured; Daunorubicin; DNA Damage; Drug Interactions; Ethylmaleimide; Etoposide; Humans; Maleimides; Topoisomerase II Inhibitors | 2002 |
Development of synthetic peptide-modified liposomes with LDL receptor targeting capacity and improved anticancer activity.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Chemistry, Pharmaceutical; Daunorubicin; Drug Delivery Systems; Humans; Leukemia, Myeloid, Acute; Liposomes; Maleimides; Mice; Mice, Nude; Peptides; Phosphatidylethanolamines; Polyethylene Glycols; Receptors, LDL; Tissue Distribution | 2014 |